Virios Therapeutics, Inc. - VIRI STOCK NEWS

Virios Therapeutics, Inc. (Nasdaq: VIRI) reported its second-quarter financial results, highlighting completed patient dosing in the Phase 2b FORTRESS fibromyalgia study. Top-line results are expected in September 2022. The company believes that its antiviral candidate, IMC-1, may improve treatment for over 100 million fibromyalgia patients, with positive Phase 2a results supporting this potential. Financially, Q2 2022 net loss narrowed to $3.7 million, or $0.44 per share, with cash reserves of $7.7 million expected to fund operations through the end of 2022.

Virios Therapeutics (Nasdaq: VIRI) announced that its Chairman and CEO, Greg Duncan, will present at the Q3 Virtual Investor Summit on August 17, 2022. The presentation will cover the company's business strategy and key catalysts. Investors can register for the event, which will include 1x1 meetings with qualified investors. Virios is focused on developing antiviral therapies for chronic diseases like fibromyalgia and has candidates IMC-1 and IMC-2 in clinical trials. More details can be found on their website.

Virios Therapeutics, Inc. (NASDAQ: VIRI) will release its second quarter 2022 financial results on August 11, 2022, before market opening. A conference call is scheduled for the same day at 8:30 a.m. ET, where management will discuss the results and provide company updates. The company is developing antiviral therapies targeting chronic diseases, primarily focusing on fibromyalgia with its lead candidate, IMC-1, under a Phase 2a clinical trial. Virios is also pursuing IMC-2 for Long COVID with an unrestricted grant to the Bateman Horne Center.

Virios Therapeutics (Nasdaq: VIRI) announced pilot study results at the University of Alabama, highlighting a significant association between gastric herpes virus infection and functional gastrointestinal disorders (FGID) such as irritable bowel syndrome and fibromyalgia. The study, published in Infection, found a marked increase in HSV-1 presence in patients with FGIDs. This suggests potential for combination antiviral therapies like IMC-1 to treat these chronic conditions. The company aims to further explore this association and enhance treatment visibility in the medical community.

Virios Therapeutics (NASDAQ: VIRI) completed enrollment in its Phase 2b FORTRESS study for IMC-1, a treatment aimed at fibromyalgia, with top-line data expected in September 2022. The company reported first-quarter financial results showing a net loss of $4.0 million ($0.48 per share) versus a loss of $3.1 million ($0.37 per share) in Q1 2021, driven by rising R&D costs. As of March 31, 2022, cash reserves stood at $11.4 million, sufficient to support operations through 2022. The firm is also pursuing IMC-2 for Long COVID symptoms under a grant to the Bateman Horne Center.

Virios Therapeutics (NASDAQ: VIRI) will announce its Q1 2022 financial results on May 12, 2022, before the market opens. A conference call will follow at 8:30 a.m. ET for management to discuss the results and provide updates. Virios focuses on antiviral therapies for chronic diseases, particularly fibromyalgia. Its lead candidate, IMC-1, has received fast track designation from the FDA and is currently in a clinical trial. The company is also pursuing IMC-2 for Long COVID management. Visit www.virios.com for more details.

Virios Therapeutics (Nasdaq: VIRI) has completed enrollment for its Phase 2b FORTRESS study, evaluating the efficacy of IMC-1, a combination antiviral therapy designed to treat fibromyalgia. The study aims to assess pain reduction among over 400 patients and is expected to yield top-line results in September 2022. IMC-1 combines famciclovir and celecoxib, targeting herpes virus suppression, and has received fast track designation from the FDA. Previous studies showed promise, with significant pain relief and better tolerance compared to placebo.

Virios Therapeutics (Nasdaq: VIRI) reported its fourth quarter and full-year financial results for 2021, highlighting significant operational progress. The Company aims to release top-line results from the Phase 2b FORTRESS study on fibromyalgia in Q3 2022. Virios also announced plans for a new exploratory study of IMC-2 targeting Long COVID, with cash reserves of $14.0 million expected to sustain operations through Q1 2023. R&D expenses increased to $10.8 million in 2021, while the net loss for the year was $16.0 million.

Virios Therapeutics (Nasdaq: VIRI) will release its fourth quarter and full year 2021 financial results on March 17, 2022, before market open. A conference call will follow at 8:30 a.m. ET for discussions on the results and corporate updates. The company is focused on developing antiviral therapies for chronic diseases, including fibromyalgia, and is advancing its lead candidate, IMC-1, in a Phase 2b trial. The company is also exploring IMC-2 for Long COVID management through collaboration with Bateman Horne Center.